Select Page

Our Keratoconus Research

Clinical research

We focus on better investigating the frequency of keratoconus worldwide. Keratoconus has been referred to as a “rare disease” for more than 30 years because it appears to occur only in a human of 2,000. In a first large-scale pilot study in the Arabic-speaking world, we have now shown that in some areas of the world the disease is up to 100 times more common than previously thought. More information can be found here .

Basic research

As a co-developer of the cross-linking of the cornea, we align our entire basic research to answer open questions from the clinic around the topic of cross-linking. For example, we were the first to cross-link ectasia after LASIK and PRK in 2007 , as well as the first to treat very thin corneas with hypo-osmolar solution in 2009. We are currently focusing on developing treatment techniques that will enable the treatment of extremely thin corneas (down to 220 μm corneal thickness).

All topics are dealt with by our teams in our two research laboratories at the Universities of Zurich and USC Los Angeles.

Our publications on keratoconus and cross-linking

Breakthrough in measuring the success of CXL for keratoconus

Breakthrough in measuring the success of Cross-Linking for keratoconus
Prof. Farhad Hafezi shows the new biomechanics CorVis ...

CXL at the Slit Lamp at ESCRS 2019

Farhad Hafezi was interviewed during ESCRS 2019, held ...

ELZA at AAO 2019

The annual meeting of the American Academy of ...

ELZA at ESCRS 2019: a record 21 presentations

The annual meeting of the European Society of ...

MEACO: ELZA goes to Jordan

The Middle East Africa Council of Ophthalmology (MEACO) ...

Cross-Linking in the USA – Part 3: Off-Label applications

Cross-Linking: Off-label applications Epi-off CXL Cross-linking the cornea ...

Cross-Linking in the USA – Part 4: The Future

PACK-CXL The process of cross-linking the cornea involves ...

The ELZA Institute

DE |